
LEI: 549300Q7EXQQH6KF7Z84
16 November 2026
RTW Biotech Opportunities Ltd
Windward Bio prices $175 million IPO
Private investment Windward completes Nasdaq IPO, RTW Bio’s fifth IPO and 17th liquidity event YTD
IPO price represents 67% step-up to prior holding value and 77 % step-up from cost
Windward’s share price closed up 68% on first day of trading
As at 31 October 2026, Windward represented 0.8% of RTW Bio’s NAV
RTW Biotech Opportunities Ltd (“RTW Bio” or the “Company”), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by private portfolio company Windward Bio Group AG (“Windward”) of the pricing of its initial public offering (“IPO”). Windward sold 10 million shares of common stock at $17 per share, for gross proceeds of approximately $175 million. Sanofi is concurrently investing $50 million in a private placement at the IPO price, bringing total gross proceeds to $225 million.
Windward is a clinical-stage biotech developing antibody medicines engineered to be long acting and offer a more convenient product presentation for patients with serious respiratory and dermatologic diseases. Its lead programme, WIN378, is being studied in asthma and chronic obstructive pulmonary disease and is currently in a Phase 2/3 trial for asthma and Phase 2 for COPD.
RTW Bio first invested $5.3 million in Windward’s Series A in January 2025 and a further $1.7 million in its $165 million Series B crossover, for a total investment of $7.0 million.
Windward began trading on the Nasdaq Global Select Market under the ticker "WWB" on 13 November 2026, where the shares traded up 68% to close at $28.50 on the day. Overall, this first day closing valuation represents a 180% step-up from RTW Bio’s prior holding value at 31 October 2026 and a 196% step-up from cost. Prior to the uplift in value, as at 31 October 2026, Windward represented 0.8% of RTW Bio’s NAV valued at $7.4 million.
Windward is RTW Bio’s tenth go-public event from its portfolio in 2026, following the IPOs of Aktis in January, Kailera in April, City Therapeutics in October and Lycia in October and five reverse or SPAC mergers announced or completed. The IPO window has reopened decisively in 2026 and public investors are placing a premium on late-stage assets with a clear durability or convenience advantage. Large-cap pharma, facing a cumulative patent cliff of approximately $170 billion by 2032, continues to look for differentiated assets. A crossover investment ahead of a listing positions RTW Bio to benefit from both dynamics.
Josh Kennedy-Smith, Partner and Head of Inflammation & Immunology at RTW Investments, LP, said, “Windward’s lead antibody targets a well-validated pathway in respiratory disease and may be dosed twice a year rather than monthly for most standard of care biologics prescribed today. This enhanced product profile compelled us to invest in the Series A, and the superb clinical execution by the team is why we added in the crossover round and at the IPO. We are excited to offer our continued support of Windward Bio as they bring their pipeline forward.
The announcement can be found here.
Enquiries:
|
RTW Investments, LP – Investment Manager Oliver Kenyon Krisha McCune (Investor Relations)
|
+44 (0)20 7959 6362 biotechopportunities@rtwfunds.com |
|
Cadarn Capital – PR & IR Partner Lucy Clark (PR) David Harris (Distribution) |
+44 (0)7984 184 461 / lucy@cadarncapital.com +44 (0)7368 883 211 / david@cadarncapital.com
|
|
Jefferies International Limited – Joint Corporate Broker Gaudi Le Roux Harry Randall-Knowles
|
+44 (0)20 7029 8000 |
|
BofA Securities – Joint Corporate Broker Edward Peel Alex Penney
|
+44 (0)20 7628 1000 |
|
Altum (Guernsey) Limited Joanna Duquemin Nicolle Sadie Morrison
|
+44 (0)1481 703 100 |
About RTW Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the website at www.rtwbio.com for more information.
***********
The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity’s business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.
The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.